Content Spotlight
Podcast: Sustainability equals efficiency, says eXmoor
eXmoor Pharma discusses the steps taken to build a more sustainable facility, the importance of its design, and calls for industry to share advice and initiatives.

The US Federal Trade Commission (FTC) has approved the acquisition of Catalent by Novo Holdings.
Deal-Making
Healthcare-focused investment firm Altaris will snap up the advanced therapies unit, including five UK and US-based facilities, from WuXi AppTec.
In addition to producing glucagon-like peptide-1 (GLP-1) drugs for an anonymous partner over five years, the Korean firm is consolidating its brands.
Facilities & Capacity
Healthcare-focused investment firm Altaris will snap up the advanced therapies unit, including five UK and US-based facilities, from WuXi AppTec.
As the year draws to a close, BioProcess Insider brings to you a wrap-up of the top biomanufacturing trends that shaped 2024.
Global Markets
Healthcare-focused investment firm Altaris will snap up the advanced therapies unit, including five UK and US-based facilities, from WuXi AppTec.
The US Federal Trade Commission (FTC) has approved the acquisition of Catalent by Novo Holdings.
Regulations
The US Federal Trade Commission (FTC) has approved the acquisition of Catalent by Novo Holdings.
Pfizer, Merck & Co., and Moderna remain upbeat over future dealings with the US government despite President-elect Trump telling vaccine-sceptic and alternative-medicine proponents to “go wild on health.”
Content Spotlight
eXmoor Pharma discusses the steps taken to build a more sustainable facility, the importance of its design, and calls for industry to share advice and initiatives.
Therapeutic Class
The agreement is expected to close by the end of 2024, expanding MilliporeSigma’s service offerings.
The London, UK-based organization says new technologies will lead to greater efficiencies and fewer failures.
Upstream & Downstream Processing
The London, UK-based organization says new technologies will lead to greater efficiencies and fewer failures.
“The field continues to evolve, and the clinical potential of mRNA extends far beyond vaccines for infectious diseases,” says Lonza mRNA business unit head.